Flavia Jacobs, Medical Research Fellow at Institute Jules Bordet, recently shared on LinkedIn:
“Don’t miss this paper!
First real-world head-to-head comparison of palbociclib, ribociclib and abemaciclib in HR+/HER2- advanced breast cancer — results from the multicenter PALMARES2 study, now published in Annals of Oncology.
- Abemaciclib and ribociclib showed better rwPFS than palbociclib overall.
- Abemaciclib was more effective than palbociclib in endocrine-sensitive patients.
- Abemaciclib and ribociclib were more effective than palbociclib in premenopausal, luminal B-like and de novo cases.
- Palbociclib had similar outcomes in older and bone-only patients.
Congrats to Leonardo Provenzano for leading this huge project. Super proud to be part of this great collaborative effort!”
“Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR+/HER2- BC patients: results from the multicenter PALMARES-2 study.”
Authors: Leonardo Provenzano et al.
